Skip to main content

Mark Mercola

NIH Rank #771
  • Program Leader
  • Top 5% Funded
  • R01 Holder
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1869864Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine

NIH Funding · FY2024

Linked Award Amount
$6.2M
Full award amounts, FY2024
Award Records
11
Records listing this PI
Award-Linked Rank
#771
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Mark Mercola. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Mark Mercola as a PI. Multi-PI records show the full award amount for context.

  • 2R01HL130020-09A1R01
    Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCs
    $776K
    award amount
  • 1R01HL171102-01R01
    Modeling Susceptibility to Radiation Therapy-induced Cardiotoxicity Using Cell Village iPSCs
    $697.9K
    award amount
  • 5R01HL146690-06R01
    Human iPSC Model to Elucidate Metabolic Interplay in Diabetic Cardimyopathy
    $672.7K
    award amount
  • 2R01HL130840-05R01
    MicroRNA Control of Dilated Cardiomyopathy
    $665.7K
    award amount
  • 2P01HL141084-06P01
    Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology
    $626.1K
    award amount
  • 1R01HL170080-01A1R01
    Evaluation of the AMPK-BACH1-NRF2 Axis as a Therapeutic Target for Inherited DCM
    $602.1K
    award amount
  • 5R01HL145676-06R01
    Single-cell Multi-omic Profiling of Drug Responses Using Pooled iPSC-CM Differentiation
    $597.1K
    award amount
  • 5R01HL152055-04R01
    Targeting the genotype to phenotype link in HCM as a therapeutic strategy
    $569.3K
    award amount
  • 5R01HL169340-02R01
    hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
    $560.4K
    award amount
  • 5R33HL167258-02R33
    High throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug development
    $444.8K
    award amount

+1 more grant not shown.

Award organization

Organizations that administered FY2024 awards listing Mark Mercola as a PI.

FY2024 award administered by Stanford University (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Stanford University
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    Entered Top 50% Nationally
    Ranked #771
  7. 2024
    Entered Top 25% Nationally
    Ranked #771
  8. 2024
    Entered Top 10% Nationally
    Ranked #771
  9. 2024
    Entered Top 5% Nationally
    Ranked #771
  10. 2025
    $10M Cumulative Funding
  11. 2025
    R01 Grant Holder
  12. 2025
    Program/Center Grant Leader